Boston Scientific has received US Food and Drug Administration (FDA) approval for its Promus Premier everolimus-eluting, platinum chromium coronary stent system. The first implantation of the system is scheduled to be performed by Martin Leon, director, Center for Interventional Vascular Therapy at Columbia University Medical Center/New York-Presbyterian Hospital, New York, USA.
According to a press release, the Promus Premier stent system offers physicians improved drug-eluting stent performance in treating patients with coronary artery disease. The stent features customised platinum chromium alloy stent architecture, an everolimus drug with a biocompatible, fluorinated co-polymer, and an enhanced stent-delivery system.
Leon said: “It is very rewarding, professionally, to be the first to provide this new drug-eluting stent therapy to my patients. Perhaps the most impressive benefit of the Promus Premier stent system is its unparalleled visibility, which combined with its enhanced customised stent architecture, leads to an advance in currently available durable polymer drug-eluting stents.”
The Promus Premier Stent System is offered in a matrix of 94 sizes, ranging in diameter from 2.25mm to 4mm and lengths of 8mm to 38mm on both monorail and over-the-wire catheter platforms. This provides physicians and their patients with a broad range of options designed to best suit their needs, it says in the press release.